검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 ORR 79.7%·t½ ~5.8 days (ADC) | ||
|---|---|---|---|
Overview Program | Enhertu (trastuzumab deruxtecan) | Disitamab Vedotin (RC48) | 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) |
Overview Company | Daiichi Sankyo / AstraZeneca | RemeGen | Yu jiren |
Overview Modality | ADC | ADC | ANTIBODY |
Overview Target | HER2 | HER2 | HER2 |
Overview Indication | HER2+ breast cancer, HER2-low, gastric | HER2+ urothelial, gastric, breast | Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction |
Overview Phase | APPROVED | APPROVED | PHASE_2 |
Overview Status | APPROVED | ACTIVE | RECRUITING |
MoA Mechanism | HER2-mediated internalization → DXd release → DNA damage | HER2-mediated delivery of MMAE | — |
MoA Biomarker | HER2 IHC/ISH | HER2 expression | — |
PK/PD Half-life | ~5.8 days (ADC) | ~5 days | — |
PK/PD Species | Mouse, Human, Tumor shrinkage, HER2 pathway suppression | Mouse | Mouse, Toxicity is manageable across all arms |
PK/PD Animal (cat.) | Human, Mouse, In vitro | Mouse, In vitro | Mouse |
PK/PD Experiment | PD | PD | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat, Hamster, Human | Mouse | Mouse, Toxicity is manageable across all arms |
Toxicology Animal (cat.) | NHP | Mouse, In vitro | Mouse |
Toxicology Major finding | ILD-like lung findings at high exposure | thrombocytopenia, demonstrated for Kadcyla and Enhertu | Perioperative FLOT Chemotherapy in Resectable Gastric Adenocarcinoma: A Single-center Retrospective Observational Study.. Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Perioperative chemotherapy improves tumor downstaging and survival rates. The FLOT regimen was proven superior in the FLOT4-AIO trial, establishing it as the standard care for resectable gastric adeno… |
Toxicology CRS | Minimal | — | — |
Clinical Primary efficacy | ORR 79.7% | ORR 50% | ORR 23.1% |
Clinical ORR | 79.7% | ~50% in HER2+ UC | 23.1% |
Clinical PFS | NA | 6.9 mo | — |
Clinical OS | NA | — | 8.97 |
Clinical Result source | ClinicalTrials.gov NCT03529110 | RC48-C009 | ClinicalTrials.gov NCT00382720 |
Clinical Data Tier / Score | S · 100 | B · 89 | C · 46 |
Clinical Program phase | APPROVED | APPROVED | PHASE_2 |
Clinical Dose / schedule | q3w | q2w | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 ORR 79.7%·t½ ~5.8 days (ADC) | ||
|---|---|---|---|
Overview Program | Enhertu (trastuzumab deruxtecan) | Disitamab Vedotin (RC48) | 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) |
Overview Company | Daiichi Sankyo / AstraZeneca | RemeGen | Yu jiren |
Overview Modality | ADC | ADC | ANTIBODY |
Overview Target | HER2 | HER2 | HER2 |
Overview Indication | HER2+ breast cancer, HER2-low, gastric | HER2+ urothelial, gastric, breast | Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction |
Overview Phase | APPROVED | APPROVED | PHASE_2 |
Overview Status | APPROVED | ACTIVE | RECRUITING |
MoA Mechanism | HER2-mediated internalization → DXd release → DNA damage | HER2-mediated delivery of MMAE | — |
MoA Biomarker | HER2 IHC/ISH | HER2 expression | — |
PK/PD Half-life | ~5.8 days (ADC) | ~5 days | — |
PK/PD Species | Mouse, Human, Tumor shrinkage, HER2 pathway suppression | Mouse | Mouse, Toxicity is manageable across all arms |
PK/PD Animal (cat.) | Human, Mouse, In vitro | Mouse, In vitro | Mouse |
PK/PD Experiment | PD | PD | PD |
Toxicology Species | Cynomolgus monkey, Mouse, Rat, Hamster, Human | Mouse | Mouse, Toxicity is manageable across all arms |
Toxicology Animal (cat.) | NHP | Mouse, In vitro | Mouse |
Toxicology Major finding | ILD-like lung findings at high exposure | thrombocytopenia, demonstrated for Kadcyla and Enhertu | Perioperative FLOT Chemotherapy in Resectable Gastric Adenocarcinoma: A Single-center Retrospective Observational Study.. Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Perioperative chemotherapy improves tumor downstaging and survival rates. The FLOT regimen was proven superior in the FLOT4-AIO trial, establishing it as the standard care for resectable gastric adeno… |
Toxicology CRS | Minimal | — | — |
Clinical Primary efficacy | ORR 79.7% | ORR 50% | ORR 23.1% |
Clinical ORR | 79.7% | ~50% in HER2+ UC | 23.1% |
Clinical PFS | NA | 6.9 mo | — |
Clinical OS | NA | — | 8.97 |
Clinical Result source | ClinicalTrials.gov NCT03529110 | RC48-C009 | ClinicalTrials.gov NCT00382720 |
Clinical Data Tier / Score | S · 100 | B · 89 | C · 46 |
Clinical Program phase | APPROVED | APPROVED | PHASE_2 |
Clinical Dose / schedule | q3w | q2w | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교